Akebia TherapeuticsAKBA
AKBA
About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Employees: 181
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
130% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 20
64% more capital invested
Capital invested by funds: $78.4M [Q3] → $129M (+$50.4M) [Q4]
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
6% more funds holding
Funds holding: 114 [Q3] → 121 (+7) [Q4]
2.83% more ownership
Funds ownership: 28.26% [Q3] → 31.09% (+2.83%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
56% less call options, than puts
Call options by funds: $335K | Put options by funds: $769K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
142%
upside
Avg. target
$6.63
167%
upside
High target
$7.50
202%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Roanna Ruiz 50% 1-year accuracy 4 / 8 met price target | 182%upside $7 | Outperform Initiated | 28 Apr 2025 |
HC Wainwright & Co. Ed Arce 40% 1-year accuracy 57 / 142 met price target | 202%upside $7.50 | Buy Reiterated | 4 Apr 2025 |
Jefferies Roger Song 28% 1-year accuracy 5 / 18 met price target | 142%upside $6 | Buy Initiated | 1 Apr 2025 |
Piper Sandler Allison Bratzel 45% 1-year accuracy 5 / 11 met price target | 142%upside $6 | Overweight Maintained | 14 Mar 2025 |
Financial journalist opinion
Based on 7 articles about AKBA published over the past 30 days
Neutral
GlobeNewsWire
23 hours ago
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C.
Neutral
Seeking Alpha
5 days ago
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call.
Positive
Zacks Investment Research
5 days ago
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
Neutral
GlobeNewsWire
6 days ago
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
1 week ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia's common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
1 week ago
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets.
Positive
Zacks Investment Research
1 month ago
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Neutral
GlobeNewsWire
1 month ago
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Neutral
GlobeNewsWire
1 month ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia's common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™